{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T20:46:46Z","timestamp":1793652406576,"version":"4.5.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,1,12]],"date-time":"2016-01-12T00:00:00Z","timestamp":1452556800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetes Ther"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1007\/s13300-015-0150-y","type":"journal-article","created":{"date-parts":[[2016,1,12]],"date-time":"2016-01-12T03:24:38Z","timestamp":1452569078000},"page":"125-137","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":54,"title":["Effect of the SGLT2 Inhibitor Dapagliflozin on Potassium Levels in Patients with Type 2 Diabetes Mellitus: A Pooled Analysis"],"prefix":"10.1007","volume":"7","author":[{"given":"Yshai","family":"Yavin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Traci A.","family":"Mansfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agata","family":"Ptaszynska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Johnsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shamik","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Johnsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,1,12]]},"reference":[{"key":"150_CR1","doi-asserted-by":"publisher","first-page":"b4114","DOI":"10.1136\/bmj.b4114","volume":"339","author":"MJ Nyirenda","year":"2009","unstructured":"Nyirenda MJ, Tang JI, Padfield PL, Seckl JR. Hyperkalaemia. BMJ. 2009;339:b4114.","journal-title":"BMJ"},{"key":"150_CR2","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1053\/ajem.2000.7344","volume":"18","author":"A Mattu","year":"2000","unstructured":"Mattu A, Brady WJ, Robinson DA. Electrocardiographic manifestations of hyperkalemia. Am J Emerg Med. 2000;18:721\u20139.","journal-title":"Am J Emerg Med"},{"key":"150_CR3","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1136\/pmj.77.914.759","volume":"77","author":"A Rastegar","year":"2001","unstructured":"Rastegar A, Soleimani M. Hypokalaemia and hyperkalaemia. Postgrad Med J. 2001;77:759\u201364.","journal-title":"Postgrad Med J"},{"key":"150_CR4","unstructured":"Brophy DF. Disorders of potassium and magnesium homeostasis. In: DiPiro JT, Talbert RL, Yee GC, et al., editors. Pharmacotherapy: a pathophysiologic approach. 9th edn. New York: McGraw-Hill; 2014."},{"key":"150_CR5","doi-asserted-by":"publisher","first-page":"e86750","DOI":"10.1371\/journal.pone.0086750","volume":"9","author":"Q Xu","year":"2014","unstructured":"Xu Q, Xu F, Fan L, et al. Serum potassium levels and its variability in incident peritoneal dialysis patients: associations with mortality. PLoS One. 2014;9:e86750.","journal-title":"PLoS One"},{"key":"150_CR6","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1136\/pgmj.71.839.551","volume":"71","author":"PR Jarman","year":"1995","unstructured":"Jarman PR, Kehely AM, Mather HM. Hyperkalaemia in diabetes: prevalence and associations. Postgrad Med J. 1995;71:551\u20132.","journal-title":"Postgrad Med J"},{"key":"150_CR7","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1056\/NEJMra1503102","volume":"373","author":"BF Palmer","year":"2015","unstructured":"Palmer BF, Clegg DJ. Electrolyte and acid-base disturbances in patients with diabetes mellitus. N Engl J Med. 2015;373:548\u201359.","journal-title":"N Engl J Med"},{"key":"150_CR8","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1136\/bmj.327.7418.812","volume":"327","author":"PR Jarman","year":"2003","unstructured":"Jarman PR, Mather HM. Diabetes may be independent risk factor for hyperkalaemia. BMJ. 2003;327:812.","journal-title":"BMJ"},{"key":"150_CR9","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1111\/j.1365-2710.2005.00638.x","volume":"30","author":"FH Ramadan","year":"2005","unstructured":"Ramadan FH, Masoodi N, El-Solh AA. Clinical factors associated with hyperkalemia in patients with congestive heart failure. J Clin Pharm Ther. 2005;30:233\u20139.","journal-title":"J Clin Pharm Ther"},{"key":"150_CR10","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.amjmed.2012.06.037","volume":"126","author":"G Liamis","year":"2013","unstructured":"Liamis G, Rodenburg EM, Hofman A, Zietse R, Stricker BH, Hoorn EJ. Electrolyte disorders in community subjects: prevalence and risk factors. Am J Med. 2013;126:256\u201363.","journal-title":"Am J Med"},{"key":"150_CR11","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S0002-9343(00)00496-4","volume":"109","author":"MA Perazella","year":"2000","unstructured":"Perazella MA. Drug-induced hyperkalemia: old culprits and new offenders. Am J Med. 2000;109:307\u201314.","journal-title":"Am J Med"},{"key":"150_CR12","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1007\/s11606-009-1228-x","volume":"25","author":"MA Raebel","year":"2010","unstructured":"Raebel MA, Ross C, Xu S, et al. Diabetes and drug-associated hyperkalemia: effect of potassium monitoring. J Gen Intern Med. 2010;25:326\u201333.","journal-title":"J Gen Intern Med"},{"key":"150_CR13","first-page":"283","volume":"73","author":"JC Hollander-Rodriguez","year":"2006","unstructured":"Hollander-Rodriguez JC, Calvert JF Jr. Hyperkalemia. Am Fam Physician. 2006;73:283\u201390.","journal-title":"Am Fam Physician"},{"key":"150_CR14","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s40264-014-0196-1","volume":"37","author":"CB Salem","year":"2014","unstructured":"Salem CB, Badreddine A, Fathallah N, Slim R, Hmouda H. Drug-induced hyperkalemia. Drug Saf. 2014;37:677\u201392.","journal-title":"Drug Saf"},{"key":"150_CR15","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1001\/archinte.1984.00350220091020","volume":"144","author":"TG Burnakis","year":"1984","unstructured":"Burnakis TG, Mioduch HJ. Combined therapy with captopril and potassium supplementation. A potential for hyperkalemia. Arch Intern Med. 1984;144:2371\u20132.","journal-title":"Arch Intern Med"},{"key":"150_CR16","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1136\/bmj.327.7407.147","volume":"327","author":"E Wrenger","year":"2003","unstructured":"Wrenger E, Muller R, Moesenthin M, Welte T, Frolich JC, Neumann KH. Interaction of spironolactone with ACE inhibitors or angiotensin receptor blockers: analysis of 44 cases. BMJ. 2003;327:147\u20139.","journal-title":"BMJ"},{"key":"150_CR17","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/0167-5273(92)90159-Z","volume":"34","author":"RT Johnston","year":"1992","unstructured":"Johnston RT, de Bono DP, Nyman CR. Preventable sudden death in patients receiving angiotensin converting enzyme inhibitors and loop\/potassium sparing diuretic combinations. Int J Cardiol. 1992;34:213\u20135.","journal-title":"Int J Cardiol"},{"key":"150_CR18","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/S0002-9343(84)80004-2","volume":"77","author":"JP Knochel","year":"1984","unstructured":"Knochel JP. Diuretic-induced hypokalemia. Am J Med. 1984;77:18\u201327.","journal-title":"Am J Med"},{"key":"150_CR19","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1046\/j.1525-1497.1997.07128.x","volume":"12","author":"MA Perazella","year":"1997","unstructured":"Perazella MA, Mahnensmith RL. Hyperkalemia in the elderly: drugs exacerbate impaired potassium homeostasis. J Gen Intern Med. 1997;12:646\u201356.","journal-title":"J Gen Intern Med"},{"key":"150_CR20","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1177\/1474651410377832","volume":"10","author":"CJ Bailey","year":"2010","unstructured":"Bailey CJ, Day C. SGLT2 inhibitors: glucuretic treatment for type 2 diabetes. Br J Diabetes Vasc Dis. 2010;10:193\u20139.","journal-title":"Br J Diabetes Vasc Dis"},{"key":"150_CR21","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nrendo.2011.243","volume":"8","author":"E Ferrannini","year":"2012","unstructured":"Ferrannini E, Solini A. SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects. Nat Rev Endocrinol. 2012;8:495\u2013502.","journal-title":"Nat Rev Endocrinol"},{"key":"150_CR22","unstructured":"FDA. Invokana (canagliflozin): Highlights of prescribing information. 2014. https:\/\/www.invokanahcp.com\/prescribing-information.pdf . Accessed October 20, 2015."},{"key":"150_CR23","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/clpt.2008.250","volume":"85","author":"B Komoroski","year":"2009","unstructured":"Komoroski B, Vachharajani N, Feng Y, Li L, Kornhauser D, Pfister M. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2\u00a0weeks in patients with type 2 diabetes mellitus. Clin Pharmacol Ther. 2009;85:513\u20139.","journal-title":"Clin Pharmacol Ther"},{"key":"150_CR24","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.2337\/dc10-0612","volume":"33","author":"E Ferrannini","year":"2010","unstructured":"Ferrannini E, Ramos SJ, Salsali A, Tang W, List JF. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care. 2010;33:2217\u201324.","journal-title":"Diabetes Care"},{"key":"150_CR25","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1016\/S0140-6736(10)60407-2","volume":"375","author":"CJ Bailey","year":"2010","unstructured":"Bailey CJ, Gross JL, Pieters A, Bastien A, List JF. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;375:2223\u201333.","journal-title":"Lancet"},{"key":"150_CR26","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.2337\/dc11-0606","volume":"34","author":"MA Nauck","year":"2011","unstructured":"Nauck MA, Del Prato S, Meier JJ, et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care. 2011;34:2015\u201322.","journal-title":"Diabetes Care"},{"key":"150_CR27","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.2337\/dc11-1693","volume":"35","author":"J Rosenstock","year":"2012","unstructured":"Rosenstock J, Vico M, Wei L, Salsali A, List JF. Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care. 2012;35:1473\u20138.","journal-title":"Diabetes Care"},{"key":"150_CR28","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1111\/j.1463-1326.2011.01434.x","volume":"13","author":"K Strojek","year":"2011","unstructured":"Strojek K, Yoon KH, Hruba V, Elze M, Langkilde AM, Parikh S. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2011;13:928\u201338.","journal-title":"Diabetes Obes Metab"},{"key":"150_CR29","doi-asserted-by":"publisher","first-page":"405","DOI":"10.7326\/0003-4819-156-6-201203200-00003","volume":"156","author":"JP Wilding","year":"2012","unstructured":"Wilding JP, Woo V, Soler NG, et al. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. Ann Intern Med. 2012;156:405\u201315.","journal-title":"Ann Intern Med"},{"key":"150_CR30","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1038\/ki.2013.356","volume":"85","author":"DE Kohan","year":"2014","unstructured":"Kohan DE, Fioretto P, Tang W, List JF. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int. 2014;85:962\u201371.","journal-title":"Kidney Int"},{"key":"150_CR31","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/S0025-7125(05)70536-8","volume":"81","author":"AK Mandal","year":"1997","unstructured":"Mandal AK. Hypokalemia and hyperkalemia. Med Clin N Am. 1997;81:611\u201339.","journal-title":"Med Clin N Am"},{"key":"150_CR32","unstructured":"International Conference on Harmonisation. Guideline for good clinical practice. 1996. http:\/\/www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Efficacy\/E6\/E6_R1_Guideline.pdf . Accessed October 20, 2015."},{"key":"150_CR33","doi-asserted-by":"publisher","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","volume":"130","author":"AS Levey","year":"1999","unstructured":"Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130:461\u201370.","journal-title":"Ann Intern Med"},{"key":"150_CR34","unstructured":"FDA. Farxiga (dapagliflozin): Highlights of prescribing information. 2014. http:\/\/www1.astrazeneca-us.com\/pi\/pi_farxiga.pdf . Accessed October 20, 2015."},{"key":"150_CR35","doi-asserted-by":"crossref","unstructured":"Lambers Heerspink HJ, de Zeeuw D, Wie L, Leslie B, List J. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab. 2013;15:853\u201362.","DOI":"10.1111\/dom.12127"},{"key":"150_CR36","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1056\/NEJMra035279","volume":"351","author":"BF Palmer","year":"2004","unstructured":"Palmer BF. Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. N Engl J Med. 2004;351:585\u201392.","journal-title":"N Engl J Med"},{"key":"150_CR37","unstructured":"FDA. Invokana (canagliflozin): Briefing Document. 2013. http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/EndocrinologicandMetabolicDrugsAdvisoryCommittee\/UCM334550.pdf . Accessed October 20, 2015."},{"key":"150_CR38","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s00467-010-1699-3","volume":"26","author":"A Lehnhardt","year":"2011","unstructured":"Lehnhardt A, Kemper MJ. Pathogenesis, diagnosis and management of hyperkalemia. Pediatr Nephrol. 2011;26:377\u201384.","journal-title":"Pediatr Nephrol"},{"key":"150_CR39","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/BF00192355","volume":"49","author":"P Widmer","year":"1995","unstructured":"Widmer P, Maibach R, Kunzi UP, et al. Diuretic-related hypokalaemia: the role of diuretics, potassium supplements, glucocorticoids and beta 2-adrenoceptor agonists. Results from the comprehensive hospital drug monitoring programme, berne (CHDM). Eur J Clin Pharmacol. 1995;49:31\u20136.","journal-title":"Eur J Clin Pharmacol"},{"issue":"Suppl 1","key":"150_CR40","first-page":"1216-P","volume":"64","author":"WT Cefalu","year":"2015","unstructured":"Cefalu WT, Leiter L, Johnsson E, Sugg J, Gause-Nilsson I. Safety and efficacy of dapagliflozin in patients with T2DM and cardiovascular disease receiving loop diuretics. Diabetes. 2015;64(Suppl 1):1216-P.","journal-title":"Diabetes"},{"key":"150_CR41","doi-asserted-by":"publisher","unstructured":"Weber MA, Mansfield TA, Alessi F, Iqbal N, Parikh S, Ptaszynska A. Dapagliflozin effects on blood pressure in hypertensive diabetic patients on renin-angiotensin system blockade. Blood Press. 2015. doi: 10.3109\/08037051.2015.1116258","DOI":"10.3109\/08037051.2015.1116258"},{"key":"150_CR42","doi-asserted-by":"publisher","unstructured":"Weber MA, Mansfield TA, Cain VA, Iqbal N, Parikh SJ, Ptaszynska A. Blood pressure and glycaemic effects of dapagliflozin in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, placebo-controlled study. Lancet Diabetes Endocrinol. 2015. doi: 10.1016\/S2213-8587(15)00417-9","DOI":"10.1016\/S2213-8587(15)00417-9"}],"container-title":["Diabetes Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-015-0150-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13300-015-0150-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-015-0150-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-015-0150-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,3]],"date-time":"2019-09-03T09:17:19Z","timestamp":1567502239000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13300-015-0150-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,12]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["150"],"URL":"https:\/\/doi.org\/10.1007\/s13300-015-0150-y","relation":{},"ISSN":["1869-6953","1869-6961"],"issn-type":[{"value":"1869-6953","type":"print"},{"value":"1869-6961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1,12]]},"assertion":[{"value":"18 November 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2016","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}